Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.43 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 12/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 7/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.37 |
| ▸ | MMP12 | P39900 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7049727 | 0.83 | CTSS (0.46) | PTPN1SRCZAP70SCN9ASCN10A | |
| SCHEMBL6467441 | 0.83 | PTPN1 (0.45) | PTPN1PTPN2EPHX2 | |
| SCHEMBL7044867 | 0.79 | CTSS (0.48) | CTSL | |
| SCHEMBL7109606 | 0.79 | CTSS (0.48) | CTSL | |
| SCHEMBL6630288 | 0.75 | FAAH (0.38) | PTPN1CYP3A4PTPN2 | |
| SCHEMBL6698500 | 0.75 | FAAH (0.38) | PTPN1CYP3A4PTPN2 | |
| SCHEMBL6698496 | 0.75 | FAAH (0.38) | PTPN1CYP3A4PTPN2 | |
| SCHEMBL6462287 | 0.74 | FAAH (0.44) | CYP3A4 | |
| SCHEMBL5731226 | 0.74 | CTSK (0.46) | SCN9AEPHX2 | |
| SCHEMBL5731227 | 0.74 | CTSK (0.46) | SCN9AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | PTPN1 1888/4885SRC 949/4885ZAP70 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.